06 Jan 2026
Dark BlueTherapeutics, located at The Oxford Science Park, has been acquired by global biopharmaceutical company Amgen, in a transaction valued at up to $840 million.
Based on unique academic insights from the University of Oxford, the team at Dark Blue Therapeutics are developing a small molecule that targets and degrades two proteins that drive specific types of acute myeloid leukemia, a fast-growing blood cancer.
Dark Blue says its... Read more